Prostaglandins as biochemical markers of radiation injury to the salivary glands after iodine-131 therapy?

被引:0
|
作者
Margarida Rodrigues
Ernst Havlik
Bernhard Peskar
Helmut Sinzinger
机构
[1] Department of Nuclear Medicine,
[2] University Hospital of Vienna,undefined
[3] Austria,undefined
[4] Department of Pharmacology,undefined
[5] University of Graz,undefined
[6] Austria,undefined
来源
关键词
Key words: Radiation injury; Iodine-131 therapy; Salivary glands; Prostaglandins; ThromboxaneIntroduction;
D O I
暂无
中图分类号
学科分类号
摘要
Because salivary glands, as well as thyroid tissue, are able to concentrate radioiodine, the treatment of thyroid diseases with iodine-131 may have secondary effects on salivary gland function which seriously impair the quality of life. Such effects include sialoadenitis and xerostomia. Salivary secretion is stimulated by prosta- glandins (PGs). In this study we evaluate whether 131I therapy influences the levels of PGs in saliva. Patients who had previously received 131I for treatment of hyperthyroidism or differentiated thyroid cancer and healthy volunteers were studied. Levels of PGs [6-oxo-PGF1α, bicyclo-PGEm, thromboxane B2 (TXB2), PGF2α] in unstimulated saliva were measured using enzyme immunoassay. Significantly lower levels of 6-oxo-PGF1α, bicyclo-PGEm and PGF2α and higher levels of TXB2 were found in the group of patients in comparison with the controls. Differences between patients and controls were more pronounced in smokers. This study demonstrates that salivary gland uptake of 131I significantly affects PG levels in saliva.
引用
收藏
页码:265 / 269
页数:4
相关论文
共 50 条
  • [21] Acute promyelocytic leukemia after iodine-131 therapy for Graves' disease
    Kolade, VO
    Bosinski, TJ
    Ruffy, EL
    PHARMACOTHERAPY, 2005, 25 (07): : 1017 - 1020
  • [22] BEWARE OF SUPPRESSED TSH IN IODINE-131 THERAPY!
    Abramowski, E.
    Sivaratnam, D.
    Hassall, S.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 33 - 33
  • [23] Hypothyroidism after iodine-131 or surgical therapy for Graves' disease hyperthyroidism
    Gómez, JM
    Gómez, N
    Amat, M
    Biondo, S
    Rafecas, A
    Jaurrieta, E
    Soler, J
    ANNALES D ENDOCRINOLOGIE, 2000, 61 (03) : 184 - 191
  • [25] Metabolic therapy with iodine-131: Removal of the radioisotope and duration of the radiation protection recommendations
    Castro Ramirez, I.
    Quinones Rodriguez, L. A.
    Iborra Oquendo, M. A.
    Seguro Fernandez, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S755 - S755
  • [26] Iodine-131 therapy in sporadic nontoxic goiter
    deKlerk, JMH
    vanIsselt, JW
    vanDijk, A
    Hakman, ME
    Pameijer, FA
    Koppeschaar, HPF
    Zelissen, PMJ
    vanSchaik, JPJ
    vanRijk, PP
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (03) : 372 - 376
  • [27] HYPOPARATHYROIDISM AFTER IODINE-131 TREATMENT OF THYROTOXICOSIS
    ORME, MCL
    CONOLLY, ME
    ANNALS OF INTERNAL MEDICINE, 1971, 75 (01) : 136 - +
  • [28] Radiation Safety Aspects of Iodine-131 metaiodobenzylguanidine (131I mIBG) Therapy Program Startup
    Barnes, J. A.
    de la Guardia, M.
    Easley, T.
    Downs, H.
    Mims, S.
    Nielson, K.
    Granger, M.
    HEALTH PHYSICS, 2018, 115 (06): : 776 - 786
  • [29] Iodine-131 tositumomab (Bexxar) in a radiation oncology environment
    Macklis, Roger M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (02): : S30 - S34
  • [30] LOW-LEVEL ASSAY OF IODINE-131 IN BIOCHEMICAL RESEARCH
    BARNABY, CF
    PLASKETT, LG
    NATURE, 1963, 200 (491) : 950 - &